Biomea (BMEA): Price to Sales

Corporate company logo of Biomea (BMEA)

Biomea Fusion, Inc. (BMEA) is depleting its accumulated reserves on costly trials, resulting in negative operating cash flow. This GURU.Markets price-to-sales chart captures market expectations, with the indicator reaching . Meanwhile, the risk of side effects in diabetes therapy could nullify the issuer's prospects. The business relies on third-party CRO/CMO contractors, creating a high level of dependency on external vendors.

Biomea Fusion - BMEA P/S Multiple (period 07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Biomea (BMEA)

- current price and projected stock value:
Price Chart biomeafusion.com|BMEA - Price Target Chart
- stock exchange capitalization data:
Market Value Biomea|BMEA - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share Biomea Fusion|BMEA - Book Capitalization|Market Capitalization to Book Value biomeafusion.com|BMEA - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient Biomea Fusion, Inc.|BMEA - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Biomea Fusion Corp|BMEA - Company Aggregate Debts|Debt to Book Capitalization Ratio Biomea|BMEA - Company Long-Term Debts|Short-Term Debt Volume Biomea Fusion|Immediate Liquidity biomeafusion.com
- financial results and valuation multiples details:
BMEA - Company Net Income|Future Profit Biomea Fusion, Inc.|BMEA - P/E Multiple|Projected Price to Earnings Ratio Biomea Fusion Inc|BMEA - PEG Multiple|EV/EBITDA Multiple Biomea|BMEA - Operating profit before deduction of amortization|Earnings per share for the trailing year Biomea Fusion|BMEA - Net earnings per share (EPS TTM)|Year-over-year net earnings per share trend for the last twelve months biomeafusion.com|BMEA - Net earnings per share growth this year|Earnings growth forecast for next year Biomea Fusion, Inc.
- issuer revenue and sales details:
BMEA - Company Revenue|Company Future Sales biomeafusion.com|BMEA - P/S Multiple|Market Cap to Expected Sales Ratio Biomea
General company analysis:biomeafusion.com BMEA
Core merchandise of Biomea Fusion, Inc.

The prospects of Biomea Fusion, Inc. (BMEA) in diabetes therapy via insurance reimbursements for innovative drugs determine the future cash flow that the market prices into the current valuation. The market cap-to-sales ratio measures the premium for the business's growth potential; therefore, the revenue multiple dynamics on GURU.Markets allow an investor to compare the asset's market valuation with its actual operational efficiency.

Competing companies

Price-to-Revenue Ratio ASND (ascendispharma.com)|Price-to-Revenue Ratio Madrigal Pharmaceuticals, Inc. MDGL|Corcept Therapeutics Inc. (CORT) - Price to Sales|RYTM - Price-to-Revenue Ratio|AKRO: Price-to-Revenue Ratio|MTSR: P/S Multiple|MLTX - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Crinetics|NewAmsterdam Pharma Company (NAMS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Soleno (SLNO)|Market Cap to Revenue Amicus Corp FOLD|P/S Multiple ETNB (89bio, Inc.)|agios.com - Price-to-Revenue Ratio|Structure Therapeutics Inc. - P/S Multiple|Price-to-Revenue Coefficient MiMedx Group Inc MDXG|Rezolute Corp (RZLT) - Price-to-Revenue Ratio|Price to Sales Lexicon Corp (LXRX)|Price-to-Revenue Ratio MBX Biosciences Inc|Market Cap to Revenue altimmune.com (ALT)|P/S Multiple AARD|SGMT - Price to Sales|P/S Multiple BIOA (BioAge Labs Inc.)|P/S Multiple Quince Therapeutics Inc QNCX|GUTS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio VTVT (vTv Therapeutics Inc.)|ATPC: P/S Multiple|Price-to-Sales Ratio PLUR (Pluri)|Market Cap to Revenue SYBX|P/S Multiple Lipocine Corporation|Price-to-Revenue Ratio Matinas BioPharma (MTNB)|Price-to-Revenue Coefficient sprucebiosciences.com|P/S Multiple GLTO (Galecto)|Price-to-Revenue Coefficient Carmell Corp. (CTCX)|LUMO - Price-to-Revenue Ratio|Price to Sales Organovo Corp|Radius Recycling, Inc. (RDUS) - Price-to-Revenue Ratio